Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs (EVOLVE)

This study has been completed.
Information provided by (Responsible Party):
Medtronic Spinal and Biologics Identifier:
First received: June 4, 2013
Last updated: November 2, 2016
Last verified: May 2016
The study objective is to collect and report 12-month outcomes pertaining to activities of daily living, quality of life, and safety parameters in a Medicare population to be treated with balloon kyphoplasty in the treatment of painful, acute, vertebral body compression fractures (VCFs) associated with either osteoporosis or cancer. The primary objective is to show statistically significant improvement from baseline in the four co-primary endpoints (SF-36v2, PCS, EQ-5D, NRS back pain and ODI) at 3-months; study success will be declared if the primary objective is met. New radiographic fractures, non-surgical management received, VCF-related healthcare resource utilization, and vertebral body height restoration data will also be collected.

Condition Intervention
Compression Fracture of Vertebral Body
Device: Balloon kyphoplasty

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures

Resource links provided by NLM:

Further study details as provided by Medtronic Spinal and Biologics:

Primary Outcome Measures:
  • Change from baseline in back function by Oswestry Disability Index [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change from baseline in back pain by Numerical Rating Scale [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change from baseline in quality of life by SF-36v2 Physical Component Summary [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change from baseline in quality of life by the EQ-5D [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 354
Study Start Date: May 2013
Study Completion Date: May 2016
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Balloon Kyphoplasty
This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
Device: Balloon kyphoplasty
The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
Other Name: BKP


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Identified as an appropriate candidate for BKP and should have made the choice to have the procedure.
  2. Must be Medicare Eligible (At least 65 years of age or otherwise eligible).
  3. Must have one to three target VCFs, located between T5 and L5, which are due to underlying primary or secondary osteoporosis or cancer.
  4. Cancer patients should not have had a change in chemotherapy regimen within the last month, nor should they have a planned change within the next month from time of enrollment, with the exception of changes in dose.
  5. All VCFs to be treated must have clinical pain symptoms (pain on palpation/percussion over the fractured vertebral body) that correlate with radiographic findings as follows:

    1. Height change: An acute (≤ four month) change in VB height or morphology from a previous x-ray, CT or MRI, with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of one or more grades by the Genant criteria20, OR
    2. Positive MRI or bone scan: VB shows hyperintense signal on STIR sequence MRI, or target VB is positive on radionuclide bone scan.
  6. All VCFs to be treated must have an estimated fracture age of four months or less.
  7. Treatment of all target VCFs must be technically feasible and clinically appropriate for balloon kyphoplasty.
  8. Pre-treatment back pain by numerical rating scale (NRS) score must be ≥ 7 (0-10 scale) and refractory to non-surgical management.
  9. Pre-treatment Oswestry Disability Index must be ≥30 (0 - 100 scale).
  10. Must have life expectancy of ≥ 12 months.
  11. Must declare availability for all study visits.
  12. Must be able to understand the risks and benefits of participating in the study and be willing to provide written informed consent.
  13. Must have the mental capacity necessary to comply with protocol requirements for the 12- month duration of study.

Exclusion Criteria:

  1. Vertebral body morphology or fracture configuration contraindicative of balloon kyphoplasty.
  2. VCFs due to high-energy trauma.
  3. Asymptomatic VCFs or prophylactic treatment of non-fractured vertebral bodies.
  4. VCFs accompanied at the same site by primary tumors of the bone (e.g., osteosarcoma), solitary plasmacytoma or osteoblastic tumors.
  5. Platelet count of <20,000/uL as measured at the time of hospital admission for the procedure.
  6. Back pain due to causes other than acute fracture.
  7. VCF with a clinically estimated (based on radiographic evidence as well as patient history) age of fracture > four months.
  8. VCF accompanied by objective evidence of secondary radiculopathy or neurologic compromise.
  9. VCFs with the need for spinal surgery beyond balloon kyphoplasty.
  10. Spinal cord compression or canal compromise requiring decompression.
  11. Significant clinical comorbidity that may either contra-indicate surgery or interfere with long-term data collection or follow-up.
  12. Pre-existing conditions contrary to balloon kyphoplasty such as:

    1. Allergy to any components (e.g., bone cement, contrast medium) of the balloon kyphoplasty device/procedure.
    2. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection.
    3. Irreversible coagulopathy or bleeding disorder.
  13. Contraindications to both MRI and radionuclide bone scan.
  14. Concurrent participation in another clinical study.
  15. Pregnant or intending to become pregnant during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01871519

  Show 25 Study Locations
Sponsors and Collaborators
Medtronic Spinal and Biologics
  More Information

Responsible Party: Medtronic Spinal and Biologics Identifier: NCT01871519     History of Changes
Other Study ID Numbers: P12-03 
Study First Received: June 4, 2013
Last Updated: November 2, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Medtronic Spinal and Biologics:
vertebral body compression fracture

Additional relevant MeSH terms:
Fractures, Bone
Fractures, Compression
Wounds and Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases processed this record on December 09, 2016